Search results
State party endorses CD3 candidate before GOP primary
The Daily Sentinel· 1 day agoThe endorsement comes one day after the party also supported one of two Republican candidates...
John Lennon's 'Mind Games' Expanded for 50th Anniversary Box
Ultimate Classic Rock· 2 days agoJohn Lennon's 'Mind Games' reissue will be released in July 2024.
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive...
Nature· 2 days agoCibisatamab is a T-cell bispecific antibody targeting the carcinoembryonic antigen (CEA) on tumor cells and CD3 epsilon chain on T cells. Here the authors report the results ...
FDA Approves Tarlatamab for Extensive-Stage SCLC
Medscape· 1 day agoContinued approval of the first-in-class bispecific T-cell engager (BiTE) may depend on proof of clinical benefit.
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE...
FOX 5 San Diego· 17 hours agoAmgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small ...
Engineered CD47 protects T cells for enhanced antitumour immunity - Nature
Nature· 2 days agoCombination of TCR or CAR T cells expressing the engineered CD47 variant 47E with anti-CD47 antibody therapy results in synergistic antitumour efficacy due to T cell resistance to clearance ...
iBio (NYSEAMERICAN:IBIO) Announces Quarterly Earnings Results
ETF DAILY NEWS· 1 day agoiBio (NYSEAMERICAN:IBIO – Get Free Report) issued its quarterly earnings results on Monday. The...
Arizona Media Association hosting debates ahead of July 30 Primary elections
Arizona Daily Sun· 3 days agoAs election season heats up, the Arizona Media Association will be hosting several debates, with the...
Earnings call: AbbVie projects robust growth and diversified pipeline By Investing.com
Investing.com· 2 days agoWith a growth platform that accounts for 80% of AbbVie's business, the company saw mid-teens growth...
Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I,...
Nature· 3 days agoChimeric antigen receptor T (CAR-T) cells have been proposed for HIV-1 treatment but have not yet demonstrated desirable therapeutic efficacy. Here, we report newly developed anti-HIV-1 CAR-T ...